Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, today announced expansion of the scope and activities of its 100%-owned subsidiary Lexaria Pharmaceutical Corp. According to the update, Lexaria Pharmaceutical will investigate how the company’s patented DehydraTECH(TM) drug delivery technology could enhance delivery and effectiveness of certain antiviral drugs in the fight against coronavirus disease COVID-19. Lexaria intends to expand collaboration with leading laboratories across North America and internationally as soon as possible.

To view the full press release, visit http://cnw.fm/4NW8h

About Lexaria

Lexaria Bioscience Corp. is a global innovator in drug delivery platforms. Its patented DehydraTECH(TM) drug delivery technology changes the way API’s enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and can reduce drug costs for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (“NSAIDs”) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, this morning announced the initiation of a program, in collaboration with leading laboratories in Canada and the USA, to analyze the benefits of Lexaria’s DehydraTECH(TM) drug delivery platform for improving delivery and effectiveness of certain antiretroviral drugs in the fight against coronavirus disease COVID-19. Researchers around the world are currently examining several antiretroviral drugs, many of which are fat soluble, as possible candidates to combat COVID-19. When administered in oral form, fat soluble drugs are known to present considerable bioavailability challenges in effectively reaching the human bloodstream. Lexaria is an established leader in oral delivery of fat-soluble drugs. Lexaria plans to conduct a pilot human pharmacokinetic exploratory study in healthy volunteers of three antiretroviral drugs that have previously been studied against other coronavirus strains, assessing DehydraTECH formulations against controls without the technology. The company intends to conduct the study at a leading Canadian University where a study design and plan has already been submitted for ethics board approval. The company has held discussions with some laboratories that could potentially expand the number of prospective drugs using DehydraTECH under evaluation for coronavirus applications. Following positive conclusions from its planned research activities, Lexaria will aggressively engage with prospective strategic partners to enhance drug development where applicable.

To view the full press release, visit http://cnw.fm/xYe8u

About Lexaria

Lexaria Bioscience Corp. is a global innovator in drug delivery technology. Its patented DehydraTECH(TM) drug delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bio-absorption; reduces time of onset; and masks unwanted tastes for orally administered bioactive molecules including nicotine, vitamins, non-steroidal anti-inflammatory drugs (NSAIDs) and other molecules. Lexaria has licensed DehydraTECH to multiple companies for use in various oral application formats, including to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed in-house research laboratory and holds a robust intellectual property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

For many, the legalization of recreational marijuana might as well have been trumpets loudly declaring the end of times. Arguments against it ranged aplenty, with some claiming it is a gateway drug while others claimed it would result in increased crime rates. But what many hadn’t considered was the effect it would have on real estate.

Economists from the University of Oklahoma ran a study to find out the effect marijuana legalization had on housing prices, and their results were quite interesting. They examined listings on Zillow, and after tracking them against legalization in Colorado and Washington State, found that legalization ‘has beneficial spillover effects at both the state and local levels.’

“Concern about the potential effect on crime rates and the difficulty in policing impaired driving have been cited as reasons to slow-walk the path to full recreational legalization. This research contributes to the discussion, providing evidence that recreational marijuana legalization (RML) has large spillover effects on the local housing market,” the study authors write.

According to the study, neighborhoods in Colorado and Washington saw a 7% price increase as marijuana retailers opened shop. “Considered together, this research suggests that there are second order benefits associated with marijuana legalization that policy makers and voters should be aware of when deciding the drug’s legal status,” the authors assert.

Apparently, marijuana dispensaries are seen as amenities, and they affect the value of the neighborhoods around them.

“Marijuana’s legalization provides a novel source of tax revenue which states have used to fund capital expenditures, especially in education and it acts as an amenity via the dispensaries that distribute it,” says the paper which was published online by the SSRN. It adds that the creation of a new legal market has direct implications for the local economy, as it establishes new dispensary jobs and reduces arrest rates. All these factors have well-established impacts in housing markets.

One of the more interesting discoveries was that while the prices of more expensive homes increased immediately following a successful ballot drive to legalize marijuana, homes in less expensive homes only saw a price increase after the stores started business. They say liquidity may be a factor as “the wealthiest households can more rapidly move to legal states if they believe there to be some positive spillover effects from legalization.”

However, they say that their research may not be able to determine whether their positive effect will persist. At the moment, though, it seems marijuana dispensaries offer a lot more than cannabis.

“This demonstrates that it is not simply the benefit of increased tax revenue, but also the existence of the dispensaries themselves that is driving the price increases. The dispensaries act as commercial amenities that the public puts a premium on being nearby.”

These study findings may come as welcome news to members of the cannabis industry, such as Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), who have always believed that the full benefits of marijuana may take long to be fully enumerated.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

On Friday, banking associations from 49 states, including Puerto Rico, sent a letter to the chairman and the highest ranking member of the Senate Banking Committee requesting them to approve the legislation seeking to protect credit unions and banks providing services to state-legal marijuana businesses.

The letter, which was addressed to Senators Mike Crapo (R-ID) and Sherrod Brown (D-OH), stressed that they are not supporting marijuana legalization, but that they are in support of legislation passed by the House. The bill would prevent federal regulators from punishing banks that are working with legal marijuana companies.

Last year, the House approved the Secure and Fair Enforcement (SAFE) Banking  Act through a bipartisan vote.

Although more and more states are seeking to legalize marijuana in one form or another, the current federal regulations prohibit banks and credit unions from doing business with marijuana companies for fear of federal sanctions.

The Associations further wrote that marijuana businesses are forced to operate on a cash basis, which compromises public safety, revenue administration, and legal compliance concerning the communities they serve. This could severely impact our local economies because revenue, which is paid to unrelated industries such as law firms, accountants, and contractors, is money, which is derived from illicit activities, and it could be construed as money laundering.

The associations representing every state except Kentucky further stated that there is an ongoing confusion over the existing policy conflicts in the industry about whether businesses that do not directly handle marijuana but supply marijuana companies with products and services that can be serviced by financial institutions.

They further wrote that if the federal laws are not amended, the entire sector of economic activity in legal marijuana might be banished from the banking system. The SAFE Banking Act respects state powers, and it does not facilitate marijuana sales in states that have opted for prohibition.

The letter concludes by beseeching  Sens. Crapo and Brown to evaluate and address the issue of banking problems, as it is within their power. And by so doing, states would benefit from immediate public safety, tax administration, and proper regulations.

Some legislators opposed the measure claiming that it would impact the legal status of marijuana as a controlled substance. Seeing this, Sen. Crapo suggested a series of restrictive amendments to the legislation, such as limiting banking access to marijuana businesses selling products containing less than 2% of THC. Advocates and industry stakeholders rejected the proposed changes.

Senator Cory Gardner said that behind closed doors, lawmakers are compromising on some of the issues and are also working through some of the objectives relating to safety, research, and guidance.

On Wednesday, the head of the Treasury Department said that the banking issue could not be handled through administrative action; therefore, it should only be dealt with legislatively.

The appeal made by the banking associations across the nation is seen as magnifying the pleas of cannabis companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) to have enabling banking laws so that state-legal marijuana businesses can access the same services as other businesses in their jurisdictions.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

On Monday, the state of Utah opened its first medical marijuana pharmacy. This has allowed patients to buy marijuana medicine legally within the state and without having to go to the other states to purchase medical cannabis and sneak the products illegally back to their homes.

The dispensary, which is known as Dragonfly Wellness located at 711 State in Salt Lake City, has marked a milestone for Utah’s medical marijuana program, which has been in the works for nearly 15 months since the voters and the lawmakers approved it.

Speaking at a press conference, the chief strategy officer at Dragonfly, Narith Panh said that for a long while they have been told what and what not to do, and now they have the chance of taking back control of their health, lifestyle, and how they manage their medical conditions.

The head of Utah’s Center for Medical Marijuana, Richard Oborn, said that the state is expected to open 14 dispensaries this year and Dragonfly is one of them.

The restauranteurs behind Sapa Sushi Bar and Grill own Dragonfly, and it is a vertically integrated pot business that has a marijuana farm and a processing facility.

On Friday morning, Oborn said that the state has started accepting applications for medical marijuana cards from patients, and the Department of Health in Utah has already issued 14 patients with medical marijuana cards. Oborn noted that about 300 patients have applied for medical marijuana cards so far.

One of the cardholders, Deanna Denmead, said that although people were using weed all around her in the 1950 and 1960s, she never tried using it because she was afraid of it and believed that it was addictive and acted as a gateway to other hard drugs. Denmead has been using opioids after her hip surgery, and they were making her sick and gave her headaches. She said that she was taking three or four ibuprofen pills at a time for knee osteoarthritis, but they did not manage to alleviate the pain completely.

On Monday, Denmead said that marijuana relieves her of the pain and that she is planning on buying a marijuana-infused salve to rub on the back of her knees and her feet to manage the pain.

An individual must have any of the conditions on the list of qualifying conditions such as cancer, epilepsy, HIV, autism, multiple sclerosis, and chronic pain to be eligible for medical marijuana cards or receive approval from marijuana certified doctors within the state.

Oborn added that they did not have any challenges with the state’s electronic patient portal over the weekend. He also said that the vendors are working together with state officials to fix problems related to website navigation and payment processing. He noted that they would keep improving the site to make it more intuitive and user-friendly.

The marijuana program manager for the Department of Agriculture and Food in Utah, Andrew Rigby, said that now that the sale of medical marijuana has been launched, the licensed marijuana cultivators in the state already have plants growing, and they are prepared to increase production as the program develops.

Dragonfly Wellness has 16 employees and will be open every day of the week from 11 a.m. to 8 p.m. It also has a community center where health professionals will host events to educate people about the use of marijuana as a medicine.

It is widely believed that industry players like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) are relieved that the medical marijuana industry in Utah is finally off the ground.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP), a global innovator in drug delivery platforms, on Wednesday announced successful processing of its first DehydraTECH(TM)-enabled liquid nanoemulsion for cannabidiol (“CBD”) beverages for one of its licensed clients. Per the update, Lexaria’s client expects to soon begin distribution of its line of CBD beverages in select stores across the U.S. Emulsified DehydraTECH processing is an additional service Lexaria can now provide to qualifying clients wanting to formulate best in class ready-to-drink beverages containing CBD. As referenced in a February 13 press release, Lexaria recently added this additional capability to its powder production facility.

To view the full press release, visit http://cnw.fm/nw1KU

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual-property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXRP

About CBDWire

CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.

To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CBDWire.com

Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask Our Editor

CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com

CBDWire is part of the InvestorBrandNetwork.

On Thursday, the House of Representatives in Vermont approved a bill legalizing retail sales of marijuana. However, the Governor, Phil Scott (R), said that he is not happy with one of the key components of the legislation.

On Wednesday, the measure garnered a strong initial vote in the House, but for the bill to formally clear the chamber, an additional vote was required, and the Members of the chamber gave a third reading approval to the legislation through a voice vote.

The approval of the measure in the Chamber was preceded by the action of the following committees; the House Government Operations, Ways and Means, and Appropriations committees where they amended and cleared the bill in the past few weeks.

In 2018, Vermont legalized the cultivation and possession of marijuana for personal use; however, the state has no legal means of purchasing/selling weed. The current legislation would resolve the purchasing challenge by establishing a commercial marijuana market. Through the bill, the state would also create several business permits and set tax rates to be imposed on legal marijuana sales.

In 2019, during the first half of the two-year legislative session, the Senate approved S. 54 in a vote of 23 to 5, and now the House and the Senate are expected to appoint a bicameral conference committee to resolve the differences between the two versions of the legislation.

Before the House made the final vote on Thursday, it took up the following amendments:

• In a voice vote, the lawmakers adopted a proposal prohibiting the advertisement of marijuana businesses but excluded labels on products, or educational and editorial materials.
• They also approved a proposal clarifying marijuana product tests would be paid for by the Department of Public Safety using the Business licensing fees instead of funds from its regulatory budget, in a voice vote.

In a vote of 48-93, the chamber rejected an amendment to expand public disclosure requirements for marijuana business applicants and their investors.

In a voice vote of 27-117, the chamber also rejected an amendment stating that law enforcement should administer saliva and breathalyzer tests in private to individuals suspected of driving under the influence. As per the bill, the samples would not be taken at the roadside, would not be used as evidence in court proceedings, and could not be used as a probable cause for arrest.

Vermont’s Governor has been pushing for law enforcement to be allowed to conduct such tests without a hassle. Scott said that impaired driving is one of the main reasons why he is opposed to commercial legalization of marijuana.

There is uncertainty on the governor’s action once the bill gets to his desk. After the House voted on Thursday, the governor said that he is not happy about the stipulation that the police must first obtain a warrant before conducting the saliva test.

Scott said that marijuana testing should be treated the same as alcohol because police officers do not need to obtain a warrant to administer alcohol impairment testing.

Top lawmakers in Vermont and administration officials said that the governor is involved in discussions about the latest marijuana reform as he is open to using tax proceeds from pot to fund an after-school program he is advocating for. On Wednesday, the chamber approved an amendment to provide funding for such initiatives.

A poll conducted by the Marijuana Policy Project found that out of four residents of Vermont, three were in favor of allowing adults to purchase cannabis.

It remains to be seen what marijuana companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) suggest as the best way to harmonize the position of the lawmakers and the governor so that the people of Vermont can have a chance to buy the marijuana products they may need.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

British Columbia-based Lexaria Bioscience (CSE: LXX) (OTCQX: LXRP) recently expanded on its relationship with Cannadips through a new definitive agreement to provide its patented DehydraTECH(TM) technology to Cannadips’ cannabis products in Cannadips’ current California market and throughout the United States (http://cnw.fm/7V8qe). An article discussing the company reads, “Lexaria’s DehydraTECH drug-delivery platform is perfectly suited to improve the dipping experience through its effective, high-absorption technology. Cannadips uses multi-spectrum oils as base ingredients. The oils are rich in high-quality terpenes, which ensure the much-coveted entourage effect. DehydraTECH minimizes the throat irritation usually associated with some terpenes. . . . ‘Lexaria is building a stronger relationship with the Cannadips brand and applying DehydraTECH to Cannadips cannabis represents our latest advance,’ Chris Bunka, CEO of Lexaria Bioscience Corp., stated in a news release. ‘Our DehydraTECH technology empowers a scalable supply chain across state lines for our cannabis brand licensees. We are excited that Cannadips is interested in activating the Lexaria technology in additional key state markets.’”

To view the full article, visit http://cnw.fm/bBmR9

About Lexaria Bioscience Corp.

Lexaria Bioscience is a global innovator in drug-delivery platforms. The company’s patented DehydraTECH drug-delivery technology changes the way active pharmaceutical ingredients enter the bloodstream, promoting healthier ingestion methods, lower overall dosing and higher effectiveness for lipophilic active molecules. DehydraTECH increases bioabsorption, reduces time of onset and masks unwanted tastes for orally administered bioactive molecules including cannabinoids, vitamins, nonsteroidal anti-inflammatory drugs (“NSAIDs”), nicotine and other molecules. Lexaria has licensed DehydraTECH to multiple companies in the cannabis industry for use in cannabinoid beverages, edibles and oral products, as well as to a world-leading tobacco producer for the development of smokeless, oral-based nicotine products. Lexaria operates a licensed, in-house research laboratory and holds a robust intellectual-property portfolio with 16 patents granted and over 60 patents pending worldwide. For more information, visit the company’s website at www.LexariaBioscience.com.

NOTE TO INVESTORS: The latest news and updates relating to LXRP are available in the company’s newsroom at http://cnw.fm/LXX

About CanadianCannabisWire

CanadianCannabisWire (CNW) is an information service that provides (1) access to our news aggregation and syndication servers, (2) CannabisNewsBreaks that summarize corporate news and information, (3) enhanced press release services, (4) social media distribution and optimization services, and (5) a full array of corporate communication solutions. As a multifaceted financial news and content distribution company with an extensive team of contributing journalists and writers, CNW is uniquely positioned to best serve private and public companies that desire to reach a wide audience of investors, consumers, journalists and the general public. CNW has an ever-growing distribution network of more than 5,000 key syndication outlets across the country. By cutting through the overload of information in today’s market, CNW brings its clients unparalleled visibility, recognition and brand awareness. CNW is where news, content and information converge.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CanadianCannabisWire.com

Please see full terms of use and disclaimers on the CanadianCannabisWire website applicable to all content provided by CNW, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW? Ask our Editor

CanadianCannabisWire (CNW)
Toronto, Ontario
www.CanadianCannabisWire.com
905.674.5977 Office
Editor@CanadianCannabisWire.com

Data from a new study shows that more older adults are using one or more marijuana product, but their doctors are not ready to discuss marijuana use with this demographic.

The new study findings published in JAMA Internal Medicine showed an increase in the percentage of adults above the age of 65 who said that they had consumed some form of marijuana within the past year. The increase was 75% higher in 2018 than it was in 2015; 4.2 % of the adults said that they had used marijuana in the past year. Marijuana consumption among the older generation has been increasing drastically since 2006 when it was recorded that less than 0.5 percent of the older generations were using cannabis.

The study author and geriatrician Benjamin Han said that the current trend in consumption of marijuana among older patients was not there ten years ago since no patient of his asked him about marijuana use ever. Han further said that marijuana questions are common questions in the clinic today. Han is an assistant professor in the division of geriatric medicine and palliative care at the New York University School of Medicine. Han said that patients ask him about marijuana consumption about once a week. He noted that there is a significant interest in the use of marijuana amongst the older generation.

The survey used data from the National Survey on Drug Use and Health and included responses from more than 14,000 people who participated in the study. Han said that the survey did not ask the older adults why they chose to use cannabis. But from his perspective, it may probably be because of the legalization of medical and adult-use marijuana as well as destigmatization of cannabis. It may also be attributed to the availability of more and more information on the use of marijuana in treating chronic conditions.

The survey revealed that a large percentage of people who have diabetes were using marijuana, probably because it helped in managing nerve pain which can be triggered by chronic pain. Han also said that an increased use of marijuana was also noted in cancer patients.

However, the study did not ask the respondents if they had arthritis, Parkinson’s disease, or chronic pain, which are all qualifying conditions, and people use marijuana to treat these ailments. A 2019 study found that older adults used marijuana to manage chronic pain, but the study did not capture all the chronic conditions that affect the older generation.

Han further said that despite the increased use of marijuana among the older generation, doctors were still not comfortable talking about weed with patients. This is mainly because of the lack of enough evidence on its medical use since older adults are usually excluded from clinical trials. Doctors should offer these patients with consultation services before they consume marijuana. This is because they are more vulnerable to the effects of THC. Furthermore, weed might react negatively with other prescription drugs, and since older patients with chronic conditions tend to take more medication, a doctor’s advice is essential.

It would be eye-opening to hear what established cannabis companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) have to say regarding the best way to get medical professionals to guide older adults as they use different forms of marijuana.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.

The lawmakers in the state of Maine are considering approving a proposal that provides a cloak of secrecy about the imminent adult-use marijuana sector.

The legislation L.D. 2091, which was written by the legislators within the state of Maine, would exclude trade secrets, security, and operating protocols provided to the state by marijuana businesses from public records law.

The state of Maine claims that the proposal would enclose in protections for cannabis business proprietary information, such as recipes for marijuana edibles.

The spokesperson for the Office of Marijuana Policy in Maine, which drafted the legislation L.D.2091, David Heidrich said that it would be the responsibility of the legislature to determine if the benefits of an exclusion outpace the need for public review.

Speaking to Portland Press Herald, Heidrich said that the Office of Marijuana Policy believes that the proposal outweighs the inability of public review.

The legislation aims to modify the Freedom of Access Act to remove application materials provided to the Office of Marijuana Policy relating to trade secrets, security, and standard operating protocols from the definition of ‘public record.’

Public records advocates and journalists have openly criticized the bill. The association that represents all the state’s daily papers within the state, The Maine Press Association, is also opposing the bill.  A lawyer in the state of Maine, Matt Warner, said that the Freedom of Access Act has been acting as a weapon between competitors in the state’s legal marijuana marketplace. Warner said that the Freedom of Access Act is an essential fundamental public right.

Voters approved the legalization of adult-use marijuana within the state in 2016. Marijuana businesses are expected to launch and start serving customers in the spring of 2020.

The state started accepting permit applications for recreational marijuana sales as well as license applications for growing and manufacturing cannabis in December 2019. Recreational marijuana was approved by voters back in 2016, and the delay in launching adult-use marijuana law on cultivation, manufacturing, and sales has been due to the legislation blockage imposed by the state’s Governor Paul LePage.

The governor opposed the bill in 2017, hence the law couldn’t be passed.

In his veto letter, the governor said that the dangers of legalizing cannabis and normalizing its consumption in the society should not be understated. He further noted that the state is dealing with a severe drug epidemic that causes the death of more than one person a day through opiate overdoses. LePage also said that legalizing marijuana would be telling the young adults in the state that some drugs are legal within Maine, and this could result in unintended and grave consequences.

The election of a new governor, Janet Mills, helped speed up marijuana reform by signing legislation that established regulations governing the sale of adult-use marijuana in June of 2018.

It remains to be seen what pot companies like Lexaria Bioscience Corp. (CSE: LXX) (OTCQX: LXRP) think about this move to exclude sensitive proprietary marijuana business information from the ambit of the Freedom of Access Act in Maine.

About CNW420

CNW420 spotlights the latest developments in the rapidly evolving cannabis industry through the release of two informative articles each business day. Our concise, informative content serves as a gateway for investors interested in the legalized cannabis sector and provides updates on how regulatory developments may impact financial markets. Articles are released each business day at 4:20 a.m. and 4:20 p.m. Eastern – our tribute to the time synonymous with cannabis culture. If marijuana and the burgeoning industry surrounding it are on your radar, CNW420 is for you! Check back daily to stay up-to-date on the latest milestones in the fast -changing world of cannabis.

To receive instant SMS alerts, text CANNABIS to 21000 (U.S. Mobile Phones Only)

For more information please visit https://www.CNW420.com

Please see full terms of use and disclaimers on the CannabisNewsWire website applicable to all content provided by CNW420, wherever published or re-published: http://CNW.fm/Disclaimer

Do you have a questions or are you interested in working with CNW420? Ask our Editor

CannabisNewsWire420
Denver, Colorado
http://www.CNW420.com
303.498.7722 Office
Editor@CannabisNewsWire.com

CNW420 is part of the InvestorBrandNetwork.